prikaz prve stranice dokumenta Dugoročni ishod liječenja kroničnog hepatitisa B u djece
  Download
PDF 613.23 KB
master's thesis
Dugoročni ishod liječenja kroničnog hepatitisa B u djece
Zagreb: University of Zagreb, School of Medicine, 2014. urn:nbn:hr:105:271105
Pavičić, Katarina
University of Zagreb
School of Medicine
Department of Pediatrics

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Pavičić, K. (2014). Dugoročni ishod liječenja kroničnog hepatitisa B u djece (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:271105

Pavičić, Katarina. "Dugoročni ishod liječenja kroničnog hepatitisa B u djece." Master's thesis, University of Zagreb, School of Medicine, 2014. https://urn.nsk.hr/urn:nbn:hr:105:271105

Pavičić, Katarina. "Dugoročni ishod liječenja kroničnog hepatitisa B u djece." Master's thesis, University of Zagreb, School of Medicine, 2014. https://urn.nsk.hr/urn:nbn:hr:105:271105

Pavičić, K. (2014). 'Dugoročni ishod liječenja kroničnog hepatitisa B u djece', Master's thesis, University of Zagreb, School of Medicine, accessed 02 December 2024, https://urn.nsk.hr/urn:nbn:hr:105:271105

Pavičić K. Dugoročni ishod liječenja kroničnog hepatitisa B u djece [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2014 [cited 2024 December 02] Available at: https://urn.nsk.hr/urn:nbn:hr:105:271105

K. Pavičić, "Dugoročni ishod liječenja kroničnog hepatitisa B u djece", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2014. Available at: https://urn.nsk.hr/urn:nbn:hr:105:271105

Metadata
TitleDugoročni ishod liječenja kroničnog hepatitisa B u djece
Title (english)Longtime outcome of chronic HBV infection in children
AuthorKatarina Pavičić
MentorJurica Vuković (mentor)
Committee memberLjubica Rajić (predsjednik povjerenstva)
Committee memberMarija Jelušić (član povjerenstva)
Committee memberJurica Vuković (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Pediatrics)
Zagreb
Defense date and country2014-07-15, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pediatrics
Abstract
Infekcija virusom hepatitisa B i progresija u kronični hepatitis B i danas, unatoč dobroj prevenciji bolesti koja se najuspješnije provodi cijepljenjem već u rodilištu, predstavlja velik javnozdravstveni problem, posebice u dječjoj populaciji. Bolest je u svom početku podmukla, prolazi bez simptoma, a može dovesti do smrtnog ishoda uslijed razvoja komplikacija – ciroze jetre, jetrenog zatajenja i hepatocelularnog karcinoma. Upravo izbjegavanje ovih komplikacija danas predstavlja dugoročnih cilj liječenja pacijenata. Prirodni tijek bolesti prolazi kroz 4 faze koje je nužno prepoznati kako bi se liječenju pristupilo u pravome trenutku. Liječenje u dječjoj populaciji predstavlja poseban izazov i otežano je prije svega činjenicom da je za dječju populaciju trenutno odobreno svega 5 antivirusnih lijekova: interferon - alfa te 4 lijeka iz skupine nukleozidnih i nukleotidnih analoga. Problem predstavlja i odluka kada i kod koga započeti s liječenjem. Danas u svijetu ne postoji dugoročna studija koja bi sa sigurnošću odgovorila na ova pitanja. Trenutne smjernice za liječenje rezultat su dogovora svjetskih stručnjaka, i čini se kako se i danas najbolji rezultati postižu primjenom interferona. U suvremenoj medicini ciljem liječenja proglašava se negativan nalaz HBV DNK u krvi te HBeAg i HBsAg negativan status.
Abstract (english)
Hepatitis B virus infection and its progression to chronic hepatitis B virus infection is still public health issue worldwide especially in paediatric population, despite of good prevention by vaccination. In beginning, infection is silent, asymptomatic but could lead to lethal complications – cirrhosis, liver failure and hepatocellular carcinoma. Long-term outcome is therefore avoiding these complications to occur. Natural history of disease consists of 4 phases, which are important to recognize so that treatment can be started at optimal point. Treatment of chronic hepatitis B in paediatric population is very challenging, primary due to only 5 medications approved for children – interferon and 4 nucleoside and nucleotide analogues. Another problem is decision when and who to treat. There is still no long-term study that could give us certain answer. Current treatment strategies are mostly based on consensus of expert panels, and it seems that best results are given by treatment with interferon. Modern medicine suggests that treatment goals are absence of HBV DNA, HBeAg and HBsAg negative status.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:271105
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2015-11-02 15:52:34